V-LAP
Pre-clinical- Indications
- Congestive heart failure
Company intelligence / Profile preview
The V-LAP system has demonstrated safety and feasibility for patient self-management based on left atrial pressure readings. In a pilot study with up to one year follow-up, there were no device-related complications or side effects. Patients showed high adherence and significant improvements in quality-of-life measures, with reduced hospitalizations due to heart failure. Over 55 implants have been performed across Europe and Israel as of mid–2025. U.S. pivotal trials are planned.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vectorious Medical Technologies.